loader image

LATVIAN

BIOMEDICAL

RESEARCH AND STUDY CENTRE


RESEARCH AND EDUCATION IN BIOMEDICINE FROM GENES TO HUMAN

Funding: European Regional Development Fund (ERDF), Measure 1.2.1. Specific support goal “To Increase the Private Sector Investments R&D”; measure 1.2.1.2. “Support for Improvement of Technology Transfer System” “Industry‑Driven Research”

Project Title: „ Development of anti-Lyme disease vaccine candidate”

Project No.: KC-PI-2017/84

Technical and economic feasibility study and the development of commercialisation strategy that will be accomplished within the first 6 months (30 th January 2017 – 29 th July 2018)

Technical and economic feasibility study and the development of commercialisation strategy costs: 27 777,77 EUR

Principle Investigator: Dr. biol. K.Tārs

The aim of the project is development of anti-Lyme disease vaccine candidate. Within our previous projects, BMC researchers already have developed an anti-Lyme disease vaccine candidate, protectivity of which has been shown in animal models. Within the project VLP technology based anti-Lyme disease candidate will be investigated and improved.

The commercial end products of our project stage would be a licensable patent and a product up-scale technology licence.

During the 1st phase of the project, a technical and economic feasibility study and commercialisation strategy will be developed.

Information published 30.01.2018.

30.01.2018-30.04.2018

In the period from 30.01.2018-30.04.2018 the procurement regulations for procurement “Feasibility study and commercialization strategy development service ” were prepared. The purpose of the service is to define the steps to develop a product or technology from conception to market introduction, and also to analyse the choice of a more advantageous solution between assigning the right to use industrial property to another person (licensing agreement, patent sale) or creating a new business on a scientific basis, and make recommendation what information should be prepared to get potential licensees or investment funds attention and offer them the technology. The above-mentioned procurement was announced on the website of the Procurement Monitoring Bureau on 20.03.2018.

KPMG Baltics Ltd. was recognized as the winner in the procurement.

Information published 27.04.2018.

01.05.2018-30.07.2018

During the reporting period continue work to the development of the Technically Economic feasibility study and the Commercialisation strategy with “KPMG Baltics”.

Published 30.07.2018.